FirstHealth of the Carolinas

Summary

FirstHealth of the Carolinas is a medical facility located in Pinehurst, North Carolina. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Endometrial Cancer, Breast Cancer, Follicular Lymphoma and other specialties. FirstHealth of the Carolinas is involved with conducting 17 clinical trials across 33 conditions. There are 2 research doctors associated with this hospital, such as Charles S. Kuzma and Michael J. Sundborg, MD.

Top PIs

Clinical Trials running at FirstHealth of the Carolinas

Lung Cancer

Non-Small Cell Lung Cancer

Endometrial Cancer

Follicular Lymphoma

Colorectal Cancer

Cancer

Parkinson's disease

Non-Hodgkin's Lymphoma

Endometrial Adenocarcinoma

Telisotuzumab Vedotin vs. Docetaxel

for Non-Small Cell Lung Cancer

This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.

Recruiting

2 awards

Phase 3

12 criteria

Tolododekin Alfa + Cetrelimab

for Non-Small Cell Lung Cancer

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.

Recruiting

1 award

Phase 1

5 criteria

JNJ-90301900 + Chemoradiation

for Lung Cancer

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Recruiting

1 award

Phase 2

3 criteria